On August 25, 2022 CDx Diagnostics, Inc. reported that the WATS3D diagnostic platform has been incorporated in the American Gastroenterological Association (AGA) Clinical Practice Update (CPU) on New Technology and Innovation for Surveillance and Screening in Barrett’s Esophagus: Expert Review, published in Clinical Gastroenterology and Hepatology (Press release, CDx Diagnostics, AUG 25, 2022, View Source [SID1234618685]). WATS3D uses a unique wide-area sampling instrument, proprietary 3D imaging with AI analysis, and expert pathologists to reliably identify abnormal cells to help physicians prevent esophageal cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The CPU is based on a thorough review of the existing clinical literature and expert opinion. It includes several Best Practice Advice statements intended to provide gastroenterologists with real-world, actionable, practical advice on the management of BE," said Vivek Kaul, MD, FACG, FASGE, AGAF, Segal-Watson Professor of Medicine, Division of Gastroenterology, University of Rochester Medical Center. "The inclusion of WATS3D in this update is an important addition and presents an opportunity for clinicians to potentially increase their detection of BE and esophageal dysplasia, both endoscopically treatable precursors to one of the fastest growing and most fatal cancers in the United States."
WATS3D technology helps overcome the limitations associated with traditional upper endoscopy screening and surveillance methods. The CPU highlights some WATS3D clinical evidence, which demonstrated an increased yield for dysplasia detection, and that pathologic interpretation of these specimens has been shown to have significantly higher interobserver agreement, with a kappa of 0.86.
"CDx is committed to providing physicians with an AI-based diagnostic solution that empowers them to prevent esophageal cancer," said Bill Huffnagle, CEO of CDx Diagnostics. "The clinical value of adding WATS3D to the upper endoscopy screening and surveillance protocol has now been recognized by 4 major medical societies (AGA, ASGE, AFS, and SAGES). This is a significant accomplishment for CDx which underscores the clinical value of WATS3D and its continued role in preempting this potentially life-threatening disease, one patient at a time."